Pfizer Ventures — Full Portfolio

Bio Protocol is a decentralized science (DeSci) platform where people can fund, develop and govern tokenized early-stage scientific research from universities, companies and researchers.

AI & Machine LearningBiotechCrypto & Web3

Co-investorsBinance LabsBig Brain HoldingsPolymorphic CapitalSerafundSMAPE CapitalSora Ventures+2 more

Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDroia VenturesVIBPfizer Venture Investments

Normunity is a cancer immunotherapy company applying an immunology-based approach to identify novel anti-cancer targets at the interface of the immune system and cancer, using proprietary platforms and human cells and tissues.

AI & Machine LearningBiotechHealthtech

Rachel Humphrey(Founding Chief Executive Officer)Lieping Chen(Scientific Founder)Mitchell Keegan(Chief Development Officer)William LaRochelle(Chief Scientific Officer)Stacy M. Plum(Chief Technology Officer)

Co-investorsSanofi VenturesTaiho Ventures, LLCSamsara BioCapitalCanaan PartnersConnecticut InnovationsPfizer Venture Investments+3 more

BlueLight Therapeutics uses a proprietary platform based on Second Harmonic Generation (SHG) to measure real-time structural changes of biomolecules, applying this structure-driven approach to discover and develop therapeutic molecules for difficult-to-drug, high-value targets.

BiotechDeep TechSouth San Francisco, US

Co-investors5AM VenturesPfizer Venture Investments

Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDroia VenturesVIBPfizer Venture Investments

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & CEO, Co-founder)

Co-investorsAtlas VentureAscenta CapitalBessemer Venture PartnersLightspeed Venture PartnersRA CapitalPfizer Venture Investments

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsAtlas VentureMission BiocapitalPfizer Venture Investments

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.

AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US

Max Mumbach(Founding Scientist, Target Discovery)Jeffrey Verboon(Founding Scientist, Computational Biology)Ansu Satpathy(Founder)Kevin Parker(Chief Executive Officer)Kevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)Ansuman Satpathy, MD, PhD(Co-founder; Board Director)

Co-investors8VCAndreessen HorowitzArtis VenturesGlobal BioAccess FundHAWKTAILPfizer Venture Investments+6 more

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDmitri Wiederschain(Executive Officer)in

BoardAlexandra Cantley(Director)inSakae Asanuma(Director)inBriggs Morrison(Executive Officer, Director, Promoter)inIrena Melnikova(Director)in

Co-investorsMPM BioImpactPfizer Venture InvestmentsPolaris PartnersTaiho Ventures, LLC

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

Nenad Grmusa(Chief Executive Officer)John McCabe(Chief Financial and Operating Officer)

Co-investorsAlta PartnersAstellas Venture Management LLCDC Investment PartnersLongwood FundPfizer Venture InvestmentsUTokyo Innovation Platform Co. Ltd.+1 more

Flare provides software infrastructure and operational support for emergency response teams in government and private sectors, enabling real-time resource management, location tracking, and coordination across multiple agencies to improve response times and effectiveness.

Enterprise SoftwareGovTechSaaSNairobi, KE

Co-investors4Di CapitalInovia CapitalAgent CapitalBase10 PartnersCasdin CapitalInvus+3 more

Flare is a layer 1 blockchain designed for data-intensive decentralized applications, providing enshrined data protocols and infrastructure for developers building with on-chain data.

Crypto & Web3Data & Infrastructure

Co-investorsDigital Currency GroupAgent CapitalBase10 PartnersCasdin CapitalInovia CapitalInvus+3 more

Flare develops AI-driven systems to manage essential workers—such as drivers, cleaners, security guards, and domestic workers—in emerging markets, vertically integrating its technology platform, worker staffing (via subsidiary Drive-Z), and customer implementation.

AI & Machine LearningFuture of WorkHR TechTokyo, JP

Kazuki Kamiya(CEO)Satoru Ichihara(COO)Shinya Hayashi(CSO)Hidefumi Iwaki(CFO)Tomohiro Sasaki(Executive Officer (Product Development))

Co-investorsANOBAKACARTA VENTURES, Inc.Spiral VenturesAgent CapitalBase10 PartnersCasdin Capital+5 more

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

BiotechDigital HealthHealthtechMedical DevicesOxford, GB

Peter Joyce(Co-founder)Tom McCarthy(Co-founder)

Co-investorsAndera PartnersCanaan PartnersOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalEarlybird Venture Capital

Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.

BiotechHealthtechMedical Devices

Co-investorsBioMedPartnersLightspeed Venture PartnersMission BiocapitalPfizer Venture Investmentsredalpine

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)Paul Yaworsky, PhD(CSO)inRahul Ballal(Executive Officer, Director)Brian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Co-investorsLongwood FundMission BiocapitalNovartis Venture FundOno Venture Investment, Inc.Pfizer Venture InvestmentsShangBay Capital LLC+2 more

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)

Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova Partners

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM VenturesOxford Science EnterprisesPfizer Venture InvestmentsBritish Patient CapitalJJDC

BiotechWaltham, US

James W. Broderick(Executive Officer, Director)John Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)

BoardJens Eckstein(Director)

Co-investorsSR One Capital ManagementTakeda VenturesVertex Ventures HC

Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.

AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US

Daniel Rhodes(Executive Officer, Director)Matthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)

BoardChristopher O'Donnell(Director)inDavid Rubin(Director)inJames Pavlik(Director)in

Co-investorsArboretum VenturesPfizer Venture InvestmentsDeerfield Management CompanyMerck Global Health Innovation Fund